New Watson post on YMB: Out on my limb Congrat
Post# of 30027
Posted On: 07/25/2014 12:19:07 PM
New Watson post on YMB:
Out on my limb
Congrats to all longs on your success so far supporting AMBS. Very nice to see and well deserved. Always remember that it's more about people than money, the money comes as a result of your caring to help small companies like this sustain. Next week I am under a high suspicion you'll hear news that places this company into the black by Q2 2015. It will also place valuation on Lympro based on studies and timetable to execute to market, I am suspecting revs into the 250m annually in '15 and up to 600m in '16. I am also expecting the partner news on the diagnostic and on the distribution next week, sensitivity is going to be far superior to Amyvid and pricing for CMS will be even more superior. Back up governmental reimbursement and you have yourselves one hell of a fun week. Wish everyone the best, this company hasn't even scratched the surface yet. All opinions, all my best guesses and that's all folks.
Out on my limb
Congrats to all longs on your success so far supporting AMBS. Very nice to see and well deserved. Always remember that it's more about people than money, the money comes as a result of your caring to help small companies like this sustain. Next week I am under a high suspicion you'll hear news that places this company into the black by Q2 2015. It will also place valuation on Lympro based on studies and timetable to execute to market, I am suspecting revs into the 250m annually in '15 and up to 600m in '16. I am also expecting the partner news on the diagnostic and on the distribution next week, sensitivity is going to be far superior to Amyvid and pricing for CMS will be even more superior. Back up governmental reimbursement and you have yourselves one hell of a fun week. Wish everyone the best, this company hasn't even scratched the surface yet. All opinions, all my best guesses and that's all folks.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼